The Moorthy Lab has 20 years of experience in liquid chromatography-tandem mass spectrometry (LC-MS/MS) and its application in basic research, drug discovery, and development. The lab is led by Ganesh Moorthy, PhD, an expert in the application of LC-MS/MS for quantitative bioanalysis and preclinical pharmacokinetic analysis.
The lab has extensive experience with various biological sample extraction procedures, LC-MS/MS analysis, problem solving, data interpretation, and reporting of drug metabolism and pharmacokinetic studies. In addition, the lab has broad experience in design, execution and interpretation of in vitro and in vivo pharmacology studies, as well as in methods for efficiently utilizing the instruments and mentoring scientists to develop, validate, and implement robust analytical methods.
The Moorthy Lab was part of the team that discovered dabrafenib, a selective inhibitor of Raf kinases with anti-tumor activity against B-Raf driven tumors. Dabrafenib received FDA approval in 2013 for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation. The lab also contributed to the development of the MEK inhibitor, trametinib, which was approved by the Food and Drug Administration in 2013.
In addition, the lab led the efforts in the development and validation of a sensitive volumetric absorptive microsampling (VAMS) assay for voriconazole and voriconazole N-oxide in human whole blood. Current research in the lab focuses on the development, validation, and implementation of VAMS assays for analysis of cefepime, vancomycin, and cannabinoids.